Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort

Journal Article · Wed Aug 15 04:00:00 EDT 2018 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2018.04.033· OSTI ID:23065551

Jones, Christopher M. ^[1]; Adams, Richard ^[2]; Downing, Amy ^[1]; Glynne-Jones, Rob; Harrison, Mark ^[3]; Hawkins, Maria ^[4]; Sebag-Montefiore, David ^[1]; Gilbert, Duncan C. ^[5]; Muirhead, Rebecca ^[6]

---

1. Leeds Institute of Cancer and Pathology, University of Leeds, Leeds (United Kingdom)
2. Centre for Trials Research, Cardiff University, Cardiff (United Kingdom)
3. Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood (United Kingdom)
4. CRUK MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford (United Kingdom)
5. Sussex Cancer Centre, Royal Sussex County Hospital, Brighton (United Kingdom)
6. Oxford Cancer and Haematology Centre, Oxford University Hospitals, Oxford (United Kingdom)

Chemoradiation therapy (CRT) with mitomycin C (MMC) and 5-fluorouracil (5-FU) is established as the standard of care for the radical treatment of patients with anal squamous cell carcinoma (ASCC). The use of the oral fluoropyrimidine-derivative capecitabine is emerging as an alternative to 5-FU despite limited evidence of its tolerability and toxicity.

• OSTI ID: 23065551
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 101; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CARCINOMAS
FLUOROURACILS
MITOMYCIN
PATIENTS
RADICALS
RADIOTHERAPY
TOXICITY